Literature DB >> 28541556

Microbiological Persistence in Patients With Mycobacterium avium Complex Lung Disease: The Predictors and the Impact on Radiographic Progression.

Sheng-Wei Pan1,2,3, Chin-Chung Shu4,5,6, Jia-Yih Feng1,2, Jann-Yuan Wang4, Yu-Jiun Chan3,7,8, Chong-Jen Yu4, Wei-Juin Su1,2.   

Abstract

BACKGROUND: Persistent growth of Mycobacterium avium complex (MAC) in the lungs indicates continuous infection in MAC lung disease (MAC-LD), but its clinical significance has not been investigated. We aimed to evaluate the predictors of persistent culture-positivity for MAC (MAC-PP) and its impact on radiographic deterioration in MAC-LD.
METHODS: Patients with MAC-LD at multiple medical centers from 2011 to 2016 were enrolled retrospectively. Microbiological persistence of MAC-LD was defined as MAC-PP exceeding 1 year, in contrast with the negative-conversion group. The outcome was radiographic progression, namely, increased number of involved lung areas or cavitary formation.
RESULTS: Among 126 patients with MAC-LD, 75 (60%) were in the MAC-PP group; these patients had a higher proportion of radiographic progression (54%) than patients in the negative-conversion group (odds ratio [OR], 3.318; 95% confidence interval, 1.146-9.612). Independent predictors of MAC-PP were low body mass index (BMI), radiographic nodular-bronchiectatic (NB) pattern, and increase in the highest grade of acid-fast bacilli smear (AFS). Patients with BMI <21 kg/m2, NB pattern, and positive AFS had an OR of 17.7 for MAC-PP, and those with ≥2 of the factors had a 4.5-fold increased OR for MAC-PP relative to the comparison group. Other than MAC-PP, the highest AFS grade and no anti-MAC treatment were correlated with radiographic progression.
CONCLUSION: Microbiological persistence in patients with MAC-LD is not uncommon and leads to an increased risk of radiographic progression. The predictors of MAC-PP are low BMI, NB pattern, and high AFS grade; if these risk factors are present, anti-MAC treatment should be seriously considered.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Mycobacterium avium complex (MAC); body mass index (BMI); microbiological persistence; nontuberculous Mycobacterium (NTM); predictor

Mesh:

Substances:

Year:  2017        PMID: 28541556     DOI: 10.1093/cid/cix479

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

1.  Pulmonary mycobacterial infection is associated with increased mortality in patients with acute respiratory distress syndrome.

Authors:  Jong Hwan Jeong; Manbong Heo; Sunmi Ju; Seung Jun Lee; Yu Ji Cho; Yi Yeong Jeong; Jong Deog Lee; Jung-Wan Yoo
Journal:  Medicine (Baltimore)       Date:  2021-08-20       Impact factor: 1.817

2.  Old age is associated with worse treatment outcome and frequent adverse drug reaction in Mycobacterium avium complex pulmonary disease.

Authors:  Joong-Yub Kim; Na Young Kim; Hee-Won Jung; Jae-Joon Yim; Nakwon Kwak
Journal:  BMC Pulm Med       Date:  2022-07-14       Impact factor: 3.320

3.  Clinical risk factors related to treatment failure in Mycobacterium abscessus lung disease.

Authors:  Keiji Fujiwara; Koji Furuuchi; Akio Aono; Fumiko Uesugi; Tatsuya Shirai; Keitaro Nakamoto; Takafumi Shimada; Fumi Mochizuki; Yoshiaki Tanaka; Hiroaki Iijima; Takashi Yoshiyama; Yuji Shiraishi; Atsuyuki Kurashima; Ken Ohta; Satoshi Mitarai; Kozo Morimoto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-09-01       Impact factor: 3.267

4.  Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection against Mycobacterium avium infection but is ineffective as an adjunct to antibiotic treatment in chronic disease.

Authors:  Ju Mi Lee; Jiyun Park; Steven G Reed; Rhea N Coler; Jung Joo Hong; Lee-Han Kim; Wonsik Lee; Kee Woong Kwon; Sung Jae Shin
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

5.  Predictors of developing Mycobacterium kansasii pulmonary disease within 1 year among patients with single isolation in multiple sputum samples: A retrospective, longitudinal, multicentre study.

Authors:  Hung-Ling Huang; Meng-Hsuan Cheng; Po-Liang Lu; Chia-Jung Liu; Inn-Wen Chong; Jann-Yuan Wang
Journal:  Sci Rep       Date:  2018-12-13       Impact factor: 4.379

6.  Serum oxidative stress in patients with pulmonary Mycobacterium avium complex disease.

Authors:  Hiroki Wakabayashi; Yasuo Matsuzawa; Sho Hayakawa; Tamako Irie; Hagino Rikitake; Ichiro Tatsuno
Journal:  Heliyon       Date:  2019-11-14

7.  Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis.

Authors:  Youngmok Park; Eun Hye Lee; Inkyung Jung; Goeun Park; Young Ae Kang
Journal:  Respir Res       Date:  2019-12-18

8.  Correlation between serum carbohydrate antigen 19-9 levels and computed tomography severity score in patients with nontuberculous mycobacterial pulmonary disease.

Authors:  Kangjoon Kim; Seung Hyun Yong; Su Hwan Lee; Sang Hoon Lee; Ah Young Leem; Song Yee Kim; Kyungsoo Chung; Eun Young Kim; Ji Ye Jung; Moo Suk Park; Young Sam Kim; Hye-Jeong Lee; Young Ae Kang
Journal:  Sci Rep       Date:  2021-02-02       Impact factor: 4.379

9.  Nutrition and Markers of Disease Severity in Patients With Bronchiectasis.

Authors:  Katherine A Despotes; Radmila Choate; Doreen Addrizzo-Harris; Timothy R Aksamit; Alan Barker; Ashwin Basavaraj; Charles L Daley; Edward Eden; Angela DiMango; Kevin Fennelly; Julie Philley; Margaret M Johnson; Pamela J McShane; Mark L Metersky; Anne E O'Donnell; Kenneth N Olivier; Matthias A Salathe; Andreas Schmid; Byron Thomashow; Gregory Tino; Kevin L Winthrop; Michael R Knowles; Mary Leigh Anne Daniels; Peadar G Noone
Journal:  Chronic Obstr Pulm Dis       Date:  2020-10

Review 10.  Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases.

Authors:  Surendra K Sharma; Vishwanath Upadhyay
Journal:  Indian J Med Res       Date:  2020-09       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.